Targeted Cancer Therapy Using VEGF-Directed Prodrug Activation
Author Information
Author(s): Spooner R A, Friedlos F, Maycroft K, Stribbling S M, Roussel J, Brueggen J, Stolz B, O'Reilly T, Wood J, Matter A, Marais R, Springer C J
Primary Institution: Cancer Research UK Centre for Cancer Therapeutics at the Institute of Cancer Research
Hypothesis
Can a fusion protein of VEGF and carboxypeptidase G2 effectively deliver a cytotoxic prodrug to cancer cells?
Conclusion
The VEGF-CPG2 fusion protein can effectively target and kill cancer cells expressing VEGFR2 by converting a non-toxic prodrug into a toxic drug.
Supporting Evidence
- VEGF-CPG2 fusion proteins can bind to VEGFR2 with high affinity.
- These fusion proteins can convert a non-toxic prodrug into a cytotoxic drug.
- VEGF115-CPG2(Q)3-H6 showed the highest specific activity and efficient secretion.
- The fusion proteins demonstrated targeted cytotoxicity in human umbilical vein endothelial cells.
Takeaway
Scientists created a special protein that helps a medicine kill cancer cells by targeting them directly, making it safer for healthy cells.
Methodology
The study involved constructing fusion proteins, expressing them in mammalian and insect cells, and testing their ability to bind to VEGFR2 and activate a prodrug.
Limitations
Some normal organs also express VEGFRs, which may lead to unintended effects.
Participant Demographics
The study involved BALB/C nude mice and human cell lines (HU-V-EC and SK-OV-3).
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website